Hypokalemic & Hyperkalemic Periodic Paralysis

1. THE 2-MINUTE PHYSIOLOGY (Rapid Pathophysiology)

• The Channelopathy Insult: Hypokalemic and hyperkalemic periodic paralysis represent a rare family of inherited, autosomal dominant skeletal muscle disorders driven by genetic defects in voltage-gated muscle ion channels (channelopathies).
• Hypokalemic Periodic Paralysis (Intracellular Shift): Sufferers of the hypokalemic form experience acute, episodic, symmetrical flaccid paralysis caused by a sudden, massive shift of extracellular potassium into the intracellular compartment. Because this is a distributional shift, the patient's total body potassium level remains completely normal. The resultant extracellular hypokalemia alters the muscle membrane's resting electrical potential, impairing normal action potential propagation and driving flaccid weakness.
• Hyperkalemic Periodic Paralysis (Extracellular Shift): Sufferers of the hyperkalemic form experience transient attacks of weakness or paralysis driven by an extracellular shift of potassium out of the cells and into the serum, resulting in elevated serum potassium with normal total body stores. The rise in extracellular potassium partially depolarizes the skeletal muscle membrane, which inactivates voltage-gated sodium channels, renders the sarcolemma unexcitable, and terminates action potential propagation.
• The Hypermetabolic Risk: Crucially, both forms of periodic paralysis are highly associated with malignant hyperthermia. The underlying channel defects increase susceptibility to uncontrolled calcium release from the sarcoplasmic reticulum, which can trigger life-threatening hypermetabolic crises when exposed to halogenated anesthetics or depolarizing paralytics.

2. THE BEDSIDE ACTION PLAN (Rapid ER Management)

• Immediate Resuscitative Stabilization:
• Airway and Ventilatory Assessment: While bulbar muscles are classically spared, progressive proximal diaphragmatic and intercostal muscle weakness can lead to neuromuscular respiratory failure.
• Perform a bedside Forced Vital Capacity (FVC) using the single-breath count test. Coach the patient to take a full inspiration and count aloud at a normal speaking pace on exhalation. A single-breath count of less than 20 indicates significant respiratory insufficiency and mandates proactive airway management.
• Airway Management Strategy: If rapid sequence intubation (RSI) is required, NEVER use Succinylcholine. Succinylcholine can precipitate fatal hyperkalemia or trigger a malignant hyperthermia crisis. Use Rocuronium (1.0–1.5 mg/kg IV); note that lower-dose non-depolarizing paralytics may be effective due to denervation-induced receptor changes.
• Hypokalemic Periodic Paralysis Protocol:
• Continuous Cardiac Monitoring: Place the patient on a cardiac monitor immediately and keep a crash cart at the bedside, as hypokalemia can induce lethal dysrhythmias and cardiac arrest.
• Careful Potassium Replacement (The Mainstay): Remember that total body potassium is normal; rebound hyperkalemia from over-correction is extremely common and dangerous.
• Oral Repletion (Preferred): Minimizes rebound hyperkalemia. Administer potassium chloride 20 to 40 mEq orally every 2 hours as needed up to a maximum of 60 mEq, checking serum potassium hourly.
• Intravenous Repletion (Reserved for life-threatening paralysis or NPO): Administer potassium chloride 10 mEq over 60 minutes via a peripheral line, or 20 mEq over 60 minutes via a central line.
• CRITICAL CONTRAINDICATION: Strictly avoid dextrose-containing fluids. Dextrose stimulates insulin release, which drives more potassium into the cells, rapidly worsening the paralysis.
• Thyrotoxic Suspicion: If Thyrotoxic Periodic Paralysis (TPP) is suspected, consider administering Propranolol 60 to 80 mg orally to blunt the hyper-adrenergic intracellular shift. If a concomitant thyroid storm is suspected, strictly avoid aspirin (which displaces thyroid hormones from binding globulin).
• Hyperkalemic Periodic Paralysis Protocol:
• Intravenous Hydration: Initiate crystalloids immediately to help rebalance extracellular potassium stores (magnesium supplementation is not indicated).
• Nebulized Beta-2 Agonists: Drive potassium back into the cells by administering nebulized albuterol 10 to 20 mg over 10 minutes (or 4 to 12 puffs via MDI with a spacer).
• Intracellular Shift (Glucose & Insulin): Administer IV dextrose combined with regular insulin. In patients with renal insufficiency, cap the regular insulin dose at a maximum of 5 units IV to avoid severe hypoglycemia.
• Frequent Monitoring: Recheck serum potassium levels every 1 to 2 hours to track response and avoid precipitous drops.

3. THE DIAGNOSTIC GRID (Differential Diagnosis & Workup)

Top 4 "Can't-Miss" Differential Diagnoses (Neuromuscular Weakness Mimics)

1. Guillain-Barré Syndrome (GBS): Presents with progressive, ascending symmetrical weakness with a classic loss of distal deep tendon reflexes (areflexia). Differentiated from periodic paralysis by its subacute progression over days to weeks and albuminocytologic dissociation in the cerebrospinal fluid.
2. Myasthenia Gravis (MG): Presents with fluctuating, fatigable skeletal, ocular, and bulbar muscle weakness (ptosis, diplopia, dysphagia). Sensation and reflexes are preserved, and weakness worsens with heat or physical stress without serum potassium shifts.
3. Acute Spinal Cord Compression (Epidural Abscess / Hematoma / Tumor): Presents with localized spine tenderness, a distinct sensory level, hyperreflexia/clonus, and acute bladder/bowel dysfunction (urinary retention).
4. Ischemic Brainstem Stroke (Basilar Artery Occlusion): Presents with sudden-onset cranial nerve palsies, dysarthria, and hemiparesis or quadriparesis.

Prioritized Diagnostic Workup Strategy

• Point-of-Care Capillary Glucose: Checked immediately on arrival to rule out hypoglycemia as a stroke and encephalopathy mimic.
• Serial Serum Electrolytes: Prioritize a metabolic panel measuring potassium, sodium, calcium, magnesium, and phosphate.
• Transtubular Potassium Gradient (TTKG): Calculated as (Urinary K+ x Plasma Osmolality) / (Urinary Osmolality x Plasma K+). In patients with paralysis and hypokalemia, a TTKG <3 mEq/L confirms periodic paralysis (indicating appropriate renal retention during an intracellular shift) and rules out renal potassium wasting.
• Spot Urine Calcium/Phosphate Ratio: A calcium/phosphate ratio greater than 1.7 on a spot urine is 100% sensitive and 96% specific for Thyrotoxic Hypokalemic Periodic Paralysis.
• Thyroid Function Panel: Order a TSH and Free T4 to screen for underlying thyrotoxicosis/hyperthyroidism.
• Creatine Kinase (CK): Checked to rule out concurrent rhabdomyolysis.
• Magnetic Resonance Imaging (MRI) of the Spine: Reserve for cases where localized spine tenderness, a sensory level, or reflex abnormalities suggest spinal cord compression.

4. THE VISUAL BOARD (ECG / POCUS / Imaging)

Electrocardiography (ECG) Checklist

• In Hypokalemic Periodic Paralysis: Check for signs of cardiotoxicity, including prominent U waves, prolonged QT intervals (long QTc), flat T waves, or ST-segment depression.
• In Hyperkalemic Periodic Paralysis: Check for signs of severe hyperkalemia, including sinus bradycardia, peaked T-waves, widening of the QRS complex, prolongation of the PR interval, or absent P waves.
• Ensure continuous rhythm monitoring is active; cardiac arrest in these states typically results from deterioration into ventricular fibrillation, pulseless electrical activity (PEA), or asystole.

Point-of-Care Ultrasound (POCUS) Checklist

• Transabdominal Bladder Scan: Measure post-void residual (PVR) volume. A PVR >100 mL suggests neurogenic urinary retention, which points away from periodic paralysis and toward spinal cord compression.
• Focused Cardiac Ultrasound (FOCUS): In patients presenting with hypotension, evaluate left ventricular contractility and inferior vena cava (IVC) diameter/collapsibility to quickly rule out cardiogenic or hypovolemic shock mimics.

Advanced Neuroimaging Checklist

• Recognize that head CT and spine MRI are expected to be normal in uncomplicated periodic paralysis. Only obtain a spine MRI if red flags (such as focal sensory levels or reflex abnormalities) suggest a compressive cord lesion.

5. SCORING MATRIX (Risk Stratification & Guidelines)

Hyperkalemic Periodic Paralysis Diagnostic Criteria

To formally support a diagnosis of hyperkalemic periodic paralysis, the clinician must document:

1. Major Criterion 1: Two or more episodes of systemic weakness associated with a documented serum potassium level >4.5 mEq/L.
2. Major Criterion 2: One episode of systemic weakness associated with a documented serum potassium level >4.5 mEq/L in a patient with a known affected relative.

Hypokalemic Periodic Paralysis Stratification

• Identify patients with a strong family history (autosomal dominant pattern).
• Differentiate familial hypokalemic periodic paralysis from Thyrotoxic Periodic Paralysis (TPP) by measuring a spot urine calcium/phosphate ratio (>1.7 indicates TPP).
• Burch-Wartofsky Point Scale (Thyroid Storm): In any patient with suspected TPP who presents with tachycardia, fever, or agitation, calculate the Burch-Wartofsky score. A score >=45 is highly suggestive of thyroid storm and mandates the aggressive initiation of antithyroid medications, beta-blockers, and stress-dose corticosteroids.

6. THE DANGER ZONE (Pitfalls & Critical Actions)

Deadly Cognitive Traps & Trainee Pitfalls

• The Rebound Hyperkalemia Pitfall (The Repletion Trap): Aggressively infusing high doses of intravenous potassium in hypokalemic periodic paralysis. Because total body potassium is normal (having merely shifted intracellularly), the potassium will eventually shift back into the extracellular space as the attack resolves. Over-repletion leads to severe, life-threatening rebound hyperkalemia.
• The Dextrose Administration Trap: Infusing dextrose-containing IV fluids to a paralyzed patient with hypokalemia. Dextrose stimulates an insulin surge, which drives more potassium into cells, precipitously worsening the hypokalemia and muscle paralysis.
• The Succinylcholine RSI Pitfall: Utilizing succinylcholine as the paralytic agent during rapid sequence intubation in a weak patient. Succinylcholine can trigger fatal hyperkalemia or precipitate a malignant hyperthermia crisis.
• Premature Closure on "Conversion Disorder": Labeling a young patient with transient, flaccid weakness as having a functional or psychiatric spell because their sensation is intact and reflexes are symmetric. Sensation is expected to be intact, and reflexes are characteristically diminished or absent in periodic paralysis.

Mandated Board-Exam Critical Actions

• Perform and document a bedside Forced Vital Capacity via the single-breath count test in any weak patient.
• Check and document a point-of-care capillary glucose immediately upon arrival.
• Obtain an immediate 12-lead ECG to screen for hypokalemic or hyperkalemic cardiotoxicity.
• Diligently avoid dextrose-containing fluids during the repletion of hypokalemic periodic paralysis.
• Check and document a spot urine calcium and phosphate to screen for Thyrotoxic Periodic Paralysis.

7. MCQ MASTERCLASS (Written Exam Tips)

High-Yield Exam "Buzzwords" and Associations

• "Sinus rhythm with prominent U waves" = Pathognomonic ECG description of hypokalemic periodic paralysis.
• "Sinus bradycardia with peaked T-waves" = Pathognomonic ECG description of hyperkalemic periodic paralysis.
• "Autosomal dominant channelopathy" = The classic genetic inheritance pattern.
• "Spot urine calcium/phosphate ratio >1.7" = Thyrotoxic periodic paralysis.
• "Transtubular Potassium Gradient (TTKG) <3 mEq/L" = Distinguishes intracellular K+ shift (periodic paralysis) from renal wasting.
• "Intracellular potassium shift with normal total body potassium stores" = The core physiological mechanism of hypokalemic periodic paralysis.

Differentiating Distractors

• The "Intravenous Potassium Bolus" Trap: Written questions will describe a weak patient with a potassium of 1.9 mEq/L and list "rapid IV potassium chloride boluses" as an option. This is a distractor. The correct answer is oral potassium replacement (20–40 mEq every 2 hours up to 60 mEq) because it has a faster repletion rate and carries a significantly lower risk of rebound hyperkalemia.
• The "Succinylcholine for RSI" Trap: Offering succinylcholine to paralyze an acutely weak patient. This is always incorrect due to the hyperkalemia and malignant hyperthermia risks. The correct choice is rocuronium.
• The "Aspirin for Thyroid Storm" Trap: If a patient has TPP and thyroid storm, aspirin is a trap because it displaces thyroid hormone from thyroxine-binding globulin, worsening the crisis.

8. THE BOARDROOM SCRIPT (OSCE & Oral Board Tips)

Triage and Stabilization Script

• "This patient presents with rapidly progressive, symmetrical flaccid paralysis. Because patients with neuromuscular weakness are at high risk for diaphragmatic failure, I will immediately assess their airway patency and check their ability to clear oral secretions. I will place the patient on a cardiorespiratory monitor, establish intravenous access, and immediately check a point-of-care capillary glucose to rule out hypoglycemia. I will perform a bedside single-breath count test to evaluate Forced Vital Capacity, recognizing that a count of less than 20 indicates significant respiratory insufficiency requiring proactive airway protection."

Mandatory Physical Exam Phrasing

• "I will perform a meticulous, focused neurological and musculoskeletal examination. I will explicitly document that sensation to light touch is fully intact and symmetrical, and that deep tendon reflexes are diminished or absent. I will assess for signs of thyroid disease, palpating the thyroid gland for enlargement, masses, or surgical scars. I will perform a transabdominal bladder ultrasound to calculate the post-void residual volume, noting that a volume greater than 100 mL would suggest neurogenic urinary retention, which points away from periodic paralysis and toward spinal cord pathology."

Diagnostics and Management Phrasing

• "I will order an immediate 12-lead ECG to evaluate for hypokalemic cardiotoxicity, such as prominent U waves and prolonged QT, or hyperkalemic signs like peaked T-waves. I will order a comprehensive metabolic panel. If I suspect hypokalaemic periodic paralysis, I will obtain a spot urine calcium and phosphate to calculate the ratio, as a ratio greater than 1.7 confirms Thyrotoxic Periodic Paralysis."
• "For patients with hypokalaemic periodic paralysis, I will initiate careful oral potassium replacement with potassium chloride 20 to 40 mEq every 2 hours, capping the total dose at 60 mEq before rechecking. I will strictly avoid dextrose-containing fluids, as dextrose stimulates insulin release and worsens intracellular K+ shifting. I will check serum potassium hourly. If the patient is unable to take oral therapy or has life-threatening paralysis, I will administer IV potassium chloride slowly, at 10 mEq over 60 minutes via a peripheral line. If hyperkalemic periodic paralysis is confirmed, I will administer nebulized albuterol 10 to 20 mg over 10 minutes to promote intracellular shifting, and initiate intravenous hydration with normal saline."

Disposition Phrasing

• "I will admit patients with their first episode of periodic paralysis, those with respiratory insufficiency or hemodynamic instability, and those with thyrotoxic periodic paralysis to a monitored setting. Patients with known, recurrent mild symptoms that have fully resolved to their baseline, with normal electrolytes and stable ECGs, can be safely considered for discharge home with close outpatient follow-up with neurology and endocrinology."